Vyndamax launch date?

When did Vyndamax (tafamidis) first get launched?

Vyndamax (tafamidis) was approved and launched in the United States in 2019, after FDA approval for transthyretin amyloid cardiomyopathy (ATTR-CM). [1]

Why do some sources list different “launch” dates for Vyndamax?

People sometimes see multiple dates because “launch” can mean different milestones:
- FDA approval date (regulatory authorization)
- Commercial availability date (when the drug is sold/distributed)
- Coverage/reimbursement start dates (when insurers begin paying)
The most commonly cited launch timing tracks the FDA approval year for Vyndamax. [1]

What’s the key regulatory context behind Vyndamax’s timing?

Vyndamax’s initial availability in the U.S. followed FDA approval for ATTR-CM. That approval is what drove the product’s first market launch in 2019. [1]

Sources:
[1] https://www.drugpatentwatch.com/patent/buy-vyndamax-tafamidis-1/